Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pan-alphavirus vaccine
- Development stage
- Preclinical
- Lead developer
- Najit Technologies
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal, Subcutaneous, Intramuscular, Transcutaneous
01
Overview
The pan-alphavirus vaccine is an inactivated whole-virus vaccine candidate being developed by Najit Technologies. It is designed to provide broad-spectrum protection against various members of the alphavirus family, including Chikungunya virus and other related alphaviruses. The vaccine is developed using Najit's proprietary HydroVax platform, which employs a photochemical inactivation process using riboflavin (Vitamin B2) and ultraviolet light. This technology is intended to preserve the natural structure of viral antigens, potentially leading to a more effective and broad immune response than traditional chemical inactivation. The project is currently in the preclinical stage of development.
- Other names
- Pan-Alphavirus
02
Targets
E1 (Alphavirus E1 glycoprotein)E2 (Alphavirus E2 glycoprotein)
Beyond the preview
Go deeper on pan-alphavirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pan-alphavirus vaccine.